ECSP055972A - 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas - Google Patents
4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicasInfo
- Publication number
- ECSP055972A ECSP055972A EC2005005972A ECSP055972A ECSP055972A EC SP055972 A ECSP055972 A EC SP055972A EC 2005005972 A EC2005005972 A EC 2005005972A EC SP055972 A ECSP055972 A EC SP055972A EC SP055972 A ECSP055972 A EC SP055972A
- Authority
- EC
- Ecuador
- Prior art keywords
- chinoclincarbonitrils
- metoxifenil
- dicloro
- alcoxi
- ischemical
- Prior art date
Links
- 230000006378 damage Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000018103 negative regulation of vascular permeability Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los compuestos de la Fórmula (I), en donde X es N, CH; n es un número entero de 1 a 3; y R y R' independientemente son alquilo de 1 a 3 átomos de carbono, y sales farmacéuticamente aceptables de dichos compuestos, con la condición de que cuando n es 1, X no puede ser N; son útiles para la inhibición de la permeabilidad vascular causada por enfermedad, lesión o algún otro trauma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44931603P | 2003-02-21 | 2003-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055972A true ECSP055972A (es) | 2006-01-16 |
Family
ID=32927510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005972A ECSP055972A (es) | 2003-02-21 | 2005-08-19 | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas |
Country Status (19)
Country | Link |
---|---|
US (1) | US20040229880A1 (es) |
EP (1) | EP1594502A1 (es) |
JP (1) | JP2006522023A (es) |
KR (1) | KR20050102133A (es) |
CN (1) | CN1750824A (es) |
AR (1) | AR043253A1 (es) |
AU (1) | AU2004216235A1 (es) |
BR (1) | BRPI0407441A (es) |
CA (1) | CA2516418A1 (es) |
CO (1) | CO5640114A2 (es) |
CR (1) | CR7931A (es) |
EC (1) | ECSP055972A (es) |
MX (1) | MXPA05008706A (es) |
NO (1) | NO20054070L (es) |
RU (1) | RU2005129333A (es) |
TW (1) | TW200423938A (es) |
UA (1) | UA80472C2 (es) |
WO (1) | WO2004075898A1 (es) |
ZA (1) | ZA200506621B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06004744A (es) * | 2003-11-06 | 2006-07-05 | Wyeth Corp | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica. |
MX2007004833A (es) * | 2004-10-22 | 2007-05-16 | Wyeth Corp | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica. |
RU2007148072A (ru) * | 2005-07-01 | 2009-08-10 | Вайет (Us) | Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения |
BR112013002182B8 (pt) | 2010-07-30 | 2023-02-28 | Oncotherapy Science Inc | Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos |
CN103772392A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
IN2014CH00840A (es) * | 2014-02-20 | 2015-09-18 | Apotex Inc | |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
US20160256457A1 (en) * | 2014-06-10 | 2016-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating or preventing acute vascular leak |
JP6744309B2 (ja) | 2014-12-02 | 2020-08-19 | イグニタ,インコーポレイテッド | 神経芽細胞腫の治療のための併用 |
WO2017029584A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Amorphous form of bosutinib |
WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
CN107814769B (zh) * | 2016-09-14 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种博舒替尼的纯化方法 |
BR112020000793A2 (pt) | 2017-07-19 | 2020-07-14 | Ignyta, Inc. | composições farmacêuticas e formas de dosagem |
JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
CN111646940B (zh) * | 2019-03-04 | 2024-01-30 | 鲁南制药集团股份有限公司 | 一种博舒替尼中间体的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
CA2500368A1 (en) * | 2002-10-04 | 2004-04-22 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
-
2004
- 2004-02-18 TW TW093103901A patent/TW200423938A/zh unknown
- 2004-02-18 US US10/780,973 patent/US20040229880A1/en not_active Abandoned
- 2004-02-19 MX MXPA05008706A patent/MXPA05008706A/es unknown
- 2004-02-19 BR BR0407441-6A patent/BRPI0407441A/pt not_active IP Right Cessation
- 2004-02-19 KR KR1020057015377A patent/KR20050102133A/ko not_active Application Discontinuation
- 2004-02-19 EP EP04712889A patent/EP1594502A1/en not_active Withdrawn
- 2004-02-19 CA CA002516418A patent/CA2516418A1/en not_active Abandoned
- 2004-02-19 JP JP2006503706A patent/JP2006522023A/ja not_active Withdrawn
- 2004-02-19 AU AU2004216235A patent/AU2004216235A1/en not_active Withdrawn
- 2004-02-19 RU RU2005129333/04A patent/RU2005129333A/ru not_active Application Discontinuation
- 2004-02-19 WO PCT/US2004/004904 patent/WO2004075898A1/en active Application Filing
- 2004-02-19 CN CNA2004800046743A patent/CN1750824A/zh active Pending
- 2004-02-19 UA UAA200508924A patent/UA80472C2/uk unknown
- 2004-02-20 AR ARP040100546A patent/AR043253A1/es not_active Application Discontinuation
-
2005
- 2005-08-03 CR CR7931A patent/CR7931A/es not_active Application Discontinuation
- 2005-08-17 CO CO05081472A patent/CO5640114A2/es not_active Application Discontinuation
- 2005-08-18 ZA ZA200506621A patent/ZA200506621B/en unknown
- 2005-08-19 EC EC2005005972A patent/ECSP055972A/es unknown
- 2005-09-01 NO NO20054070A patent/NO20054070L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA05008706A (es) | 2005-10-05 |
JP2006522023A (ja) | 2006-09-28 |
CA2516418A1 (en) | 2004-09-10 |
NO20054070L (no) | 2005-11-14 |
TW200423938A (en) | 2004-11-16 |
CO5640114A2 (es) | 2006-05-31 |
BRPI0407441A (pt) | 2006-01-31 |
US20040229880A1 (en) | 2004-11-18 |
CR7931A (es) | 2006-02-07 |
ZA200506621B (en) | 2008-02-27 |
AR043253A1 (es) | 2005-07-20 |
NO20054070D0 (no) | 2005-09-01 |
EP1594502A1 (en) | 2005-11-16 |
UA80472C2 (en) | 2007-09-25 |
AU2004216235A1 (en) | 2004-09-10 |
KR20050102133A (ko) | 2005-10-25 |
RU2005129333A (ru) | 2006-01-27 |
WO2004075898A1 (en) | 2004-09-10 |
CN1750824A (zh) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055972A (es) | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas | |
ECSP066548A (es) | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica | |
UY27918A1 (es) | Derivados de benzodioxol | |
PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
UY26512A1 (es) | Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
CR10127A (es) | Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849) | |
DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
PA8557001A1 (es) | Nuevos derivados de pirrolidina | |
UY26086A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
ES2126068T3 (es) | Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene. | |
UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
CR10376A (es) | Derivados de terfenil para el tratamiento de la enfermedad de alzheimer | |
ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
ATE279192T1 (de) | Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung | |
UY27018A1 (es) | Derivados de la pirimidina | |
MX2007011814A (es) | Compuestos citoesqueleticos activos, composiciones y usos. | |
ECSP077385A (es) | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesión isquémica | |
AU8519601A (en) | 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents | |
PA8531601A1 (es) | Nuevos heteroaromatos | |
NO20053997D0 (no) | Oligosaccharidderivat | |
CR6503A (es) | Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano | |
AR037140A1 (es) | Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende |